Telomir Pharmaceuticals, Inc

COMMUNIQUÉ DE PRESSE

publié le 09/10/2025 à 13:30, il y a 2 mois 4 jours

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Telomir Pharmaceuticals announces new findings showing Telomir-1's impact on aggressive breast cancer cells, targeting iron-dependent regulation and cellular energy pathways

Telomir-1 Telomir Pharmaceuticals Breast Cancer Cells Iron-dependent Regulation Cellular Energy Pathways
BRÈVE

publiée le 07/10/2025 à 13:35, il y a 2 mois 6 jours

Telomir Pharmaceuticals dévoile des résultats précliniques prometteurs dans le traitement du cancer de la prostate

Cancer De La Prostate Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Suppresseurs De Tumeurs
BRÈVE

publiée le 07/10/2025 à 13:35, il y a 2 mois 6 jours

Telomir Pharmaceuticals Unveils Promising Preclinical Results in Prostate Cancer Therapy

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Tumor Suppressors
COMMUNIQUÉ DE PRESSE

publié le 07/10/2025 à 13:30, il y a 2 mois 6 jours

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Telomir Pharmaceuticals unveils new preclinical findings showing Telomir-1 reactivates tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models, offering potential for improved chemotherapy response and metastasis control

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Preclinical Findings Tumor Suppressor Genes
BRÈVE

publiée le 18/09/2025 à 14:05, il y a 2 mois 25 jours

Telomir-1 Shows Expanded Targeting of Histone Demethylases

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Histone Demethylases Cancer And Aging
BRÈVE

publiée le 18/09/2025 à 14:05, il y a 2 mois 25 jours

Telomir-1 montre un ciblage élargi des déméthylases d'histones

Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Histone Demethylases Cancer Et Vieillissement
COMMUNIQUÉ DE PRESSE

publié le 18/09/2025 à 14:00, il y a 2 mois 25 jours

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Telomir Pharmaceuticals announces Telomir-1's new in vitro results inhibiting KDM5 family, expanding epigenetic therapy possibilities in cancer treatment and aging slowdown

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy KDM5 Family Inhibition Cancer Aging Treatment
BRÈVE

publiée le 09/09/2025 à 14:05, il y a 3 mois 4 jours

Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data

Cancer Research Telomir-1 Telomir Pharmaceuticals DNA Methylation CDKN2A
BRÈVE

publiée le 09/09/2025 à 14:05, il y a 3 mois 4 jours

Telomir Pharmaceuticals dévoile des données précliniques prometteuses sur le cancer

Telomir-1 Telomir Pharmaceuticals Recherche Sur Le Cancer Méthylation De L'ADN CDKN2A
COMMUNIQUÉ DE PRESSE

publié le 09/09/2025 à 14:00, il y a 3 mois 4 jours

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance

Cancer Therapy Telomir Pharmaceuticals Preclinical Findings DNA Methylation CDKN2A Gene

Publié le 12/12/2025 à 18:00, il y a 1 jour 16 heures

Disclosure of trading in own shares between November 24th and November 28th, 2025
Publié le 12/12/2025 à 18:00, il y a 1 jour 16 heures

Déclaration des transactions sur actions propres réalisées du 24 novembre au 28 novembre 2025
Publié le 12/12/2025 à 09:15, il y a 2 jours 1 heure

CHANGE IN THE SHARE CAPITAL
Publié le 12/12/2025 à 09:15, il y a 2 jours 1 heure

MODIFICATION DE CAPITAL
Publié le 11/12/2025 à 19:23, il y a 2 jours 15 heures

Eiffage is joining the CAC 40 index

Voir tout LES ECHOS COMFI WIRE

Publié le 13/12/2025 à 02:00, il y a 1 jour 8 heures

Battery X Metals Announces Confidential Submission of Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Publié le 13/12/2025 à 00:13, il y a 1 jour 10 heures

Prospect Ridge Announces Non-Brokered Private Placement
Publié le 12/12/2025 à 23:05, il y a 1 jour 11 heures

ReelTime's RLTR Stock Surges Past AI Giants Following LG Smart TV Debut of Reel Intelligence
Publié le 12/12/2025 à 22:00, il y a 1 jour 12 heures

Rektron Group Provides Corporate Updates
Publié le 12/12/2025 à 17:00, il y a 1 jour 17 heures

From Demonstration to Integration: How Sectors Actually Adopt SMX Technology

Voir tout ACCESSWIRE

Publié le 13/12/2025 à 19:57, il y a 14 heures 32 minutes

The Payments Group Holding identifies business activity fields and investment opportunities in AI company building and the biotech sector
Publié le 13/12/2025 à 17:00, il y a 17 heures 30 minutes

Tapping into "Urban Oilfield": Unlocking the Value of Waste Plastic Film
Publié le 13/12/2025 à 11:20, il y a 23 heures 10 minutes

Official streaming platform for the Games of the Future Abu Dhabi 2025 powered by ADNOC launches ahead of opening competition
Publié le 13/12/2025 à 04:15, il y a 1 jour 6 heures

M7 World Championship unveils first Opening Ceremony, tournament draw, and M7 Pass—elevates Indonesia on global stage
Publié le 12/12/2025 à 21:18, il y a 1 jour 13 heures

EQS-Adhoc: 029 Group SE: Successful completion of two strategic transactions

Voir tout EQS

News